Caris Life Sciences, Inc. Common Stock (CAI) support and resistance · rev $812.0M
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
This page maps Caris Life Sciences, Inc. Common Stock (CAI) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported CAI revenue for 2025-12-31 was $812.0M. Net income was -$68.1M. Revenue was up 97.0% from 2024-12-31 to 2025-12-31. CAI currently screens at market cap $5.22B.
CAI currently screens at market cap $5.22B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new CAI 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the CAI quote page for the session range and the stock page for the full model.
Not investment advice.